IO Biotech Inc 뉴스 - IOBT | 주식 나스닥

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in...

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in...

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival...

Form 8-K - Current report

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring...

Ph3 melanoma data for IO102-IO103 remain on track for 1H25 and represents the next key catalyst. At .70 we are trading at cash. With a positive Ph3 melanoma readout we will be trading at $3.00 overnight with a march to $6.00 towards the later half of 2025. In addition, I'm encouraged by the supportive data in additional solid tumors which increases my confidence in the potential for success in the ongoing Ph3 melanoma study.

Also lets remember the IO102-IO103 melanoma study is with Merck's + pembrolizumab Ketruda. If IOBT's IO102-IO103 is approved, it will be a disruptive game changer thus creating an overnight valuation of about 200 million for the company in 2025. Leading into 2026, we could see a valuation conservatively of about $400M. This is my opinion.

👍️0

ZLAZARUS 2 주 전

Picked up at 20,000 shares @ .88 , I will pick up more when it drops below .73

👍️0

phrocks 2 주 전

Now you're a participant??

👍️0

ZLAZARUS 3 주 전

Targeting a fill between .70 & .78 Gem here on positive IOB-013/KN-D18 Q1 2025 Phase III results.

Monk are we finally on the move with this?

👍️0

axelvento 2 월 전

O Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year
Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and IDO, and which has breakthrough therapy designation. A pivotal study in first line metastatic melanoma will read out soon.

https://www.biotechtv.com/post/io-biotech-october-11-2024

IOBT.................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783

👍️0

axelvento 2 월 전

IOBiotech
is pleased to announce that it will be presenting two posters at the SITC 2024 Annual Meeting.

The first poster presentation contains updated and expanded data from the complete cohort (n=31) from the first line (1L) cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in our Phase 2 basket trial of investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The second poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.

We look forward to sharing these exciting data at the meeting which takes place in Houston from November 6-10, 2024. See full details here:

https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Two-Poster-Presentations-at-the-Society-for-Immunotherapy-of-Cancers-SITC-39th-Annual-Meeting/default.aspx

👍️0

glenn1919 3 월 전

iobt................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783

👍️0

Monksdream 3 월 전

IOBT new 52 week low
https://investorshub.advfn.com/uimage/uploads/2024/9/12/fmdniIMG_1694.gif

starting to run into the readout
Lead investigator and advisors that helped BMS in making ipi+nivo the new SOC --- They now work on this. Cancer vaccines back in fashion.

👍️0

PonkenPlonken 4 월 전

Sorry for the late reply, im not yet fully familiar with this platform.
The SOC for advanced melanoma is Ipi + Nivo which is neither very helpful nor very safe. Hence "the bar is hanging low" here.

For us dummies, can you define SOC in this context? Thanks.

👍️0

PonkenPlonken 6 월 전

CEO made it pretty clear numerous times at Jefferies IMO
they will become the SOC, not only in advanced melanoma but in all stages.
They also think their platform can be used for non-cancer indications.

2 Birds in the hand and many more in the bush$$$

👍️0

PonkenPlonken 6 월 전

https://www.youtu be.com/watch?v=OvC-86SN9Ao&ab_channel=VJOncology

australian KOL on IOBT

many things pointing at it becoming the SOC one day...

👍️0

axelvento 6 월 전

golden cross MA50 MA200

👍️0

axelvento 7 월 전

a planned interim analysis of ORR will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024 and, if supportive, we believe could allow for submission of a BLA for accelerated approval in the US.
Cash and cash equivalents as of March 31, 2024 were $118.0 million, compared to $143.2 million at December 31, 2023. During the three months ended March 31, 2024, the company used cash, cash equivalents and restricted cash of $24.9 million. The increase in cash use was primarily driven by milestone payments and payment of other accrued expenses associated with clinical trials, as well as the payment of year-end bonuses. The company continues to expect that it will have sufficient cash to run the company into the fourth quarter of 2025.

👍️0

axelvento 7 월 전

Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee
Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors
Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025

https://www.biopharmcatalyst.com/company/IOBT/news/190095

👍️0

axelvento 7 월 전

https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Abstract-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspx

👍️0

axelvento 8 월 전

IO Biotech was founded in 2014 and just 10 years into the journey we are in a pivotal phase III trial I think that’s quite fast

👍️0

axelvento 8 월 전

next catalyst-In November 2023, the company completed enrollment of 380 patients in its pivotal Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in advanced melanoma. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS). The PFS analysis is event-driven and will be conducted when 226 events have occurred in the trial, which the company estimates will take place in the second half of 2025. Additionally, a planned interim analysis of overall response rate (ORR) will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024.

$IOBT - 👆Up 1.8% Pre-Market/ Current Price $2.00
Announces $75 Million Private Placement Financing

👍️0

The Night Stalker 1 년 전

nice

👍️0

kzivann 1 년 전

Extremely heavy volume on good news. PPS down . Lower this AM. Watching

IOBT

👍️0

Phosphene 3 년 전

IO Biotech’s (NASDAQ:IOBT ) lock-up period is set to end on Wednesday, May 4th.

https://www.defenseworld.net/2022/04/27/io-biotech-inc-s-lock-up-period-set-to-end-on-may-4th-nasdaqiobt.html

👍️0

conix 3 년 전

Bitoechs are waking up ---like they did last year.

I shopped for a number of sold out biotechs in December and picked and chose a number of sold out biotechs.

IOBT --I missed. But there are legs here. I have done well on four of my picks. Still waiting on two.

Time will tell.

👍️0

Phosphene 3 년 전

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types

https://www.globenewswire.com/news-release/2021/12/06/2346557/0/en/IO-Biotech-Announces-Third-Clinical-Collaboration-with-Merck-to-Evaluate-IO102-IO103-in-Combination-With-KEYTRUDA-pembrolizumab-as-First-Line-Treatment-in-a-Phase-2-Multi-Arm-Baske.html

👍️0

Eggplant 3 년 전

What happened? IPO at $14/sh four weeks ago, and the stock has nearly folded in half. No news, and the only sellers should be the IPO buyers, right? Mystery.

👍️0

Work Harder 3 년 전

I was right on the 7

for now

Yu tell wifeie

I appreciate her time

:}

👍️0

Phosphene 3 년 전

Did Sunstone/Verland recoup initial seed?

👍️0

Staypositive1 3 년 전

might wait till .035...lol

👍️0

Phosphene 3 년 전

IO Biotech begins trading on Nasdaq Global Market today.

IPO pps is $14.

Thu, November 4, 2021, 11:52 PM.

https://finance.yahoo.com/news/io-biotech-inc-announces-pricing-035200314.html?fr=sycsrp_catchall

Sunstone and Novo Holdings involved.

👍️0

Phosphene 3 년 전

EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED TO MYMETICS’ (MYMX) VIROSOMES IN A PRECLINICAL TUMOR MODEL

https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html

👍️0

Phosphene 3 년 전

Denmark's IO Biotech seeks $110M+ in Nasdaq debut.

https://pitchbook.com/newsletter/denmarks-io-biotech-seeks-110m-in-nasdaq-debut

https://www.fiercebiotech.com/biotech/io-biotech-raises-155m-to-trial-ido-and-pd-l1-cancer-vaccines

https://www.iobiotech.com/

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma

https://www.firstwordpharma.com/node/1783725?tsid=17

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

IO Biotech Inc (IOBT)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

IOBT 뉴스

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Form 8-K - Current report

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Announces Participation in Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

Form 8-K - Current report

IOBT Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

IO Biotech Inc (IOBT) 뉴스

IO Biotech Inc (IOBT)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

IOBT 뉴스

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Form 8-K - Current report

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

IO Biotech Announces Participation in Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

Form 8-K - Current report

IOBT Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기